Skip to content

For research use only. Not for human or animal consumption. Ships to US addresses only.

Research News

Nov 18, 2026 · 2 min readRegulatoryIncretin Analogs

EMA Committee Issues Guidance on Tirzepatide and Oral Contraceptives

EMA's CHMP adopted a communication to healthcare professionals on Mounjaro (tirzepatide) and the reliability of oral contraceptives.

The European Medicines Agency's human medicines committee (CHMP) adopted a direct healthcare professional communication (DHPC) on the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives, according to the highlights of its 9 to 12 November 2026 meeting.

What happened

In its meeting highlights, EMA lists the DHPC among the items the CHMP adopted. The agency says the marketing authorisation holder will distribute the communication to healthcare professionals following a European Commission decision, and that it will also be published on the EMA website and in national registers of EU Member States.

What the communication says

According to the EMA page, the DHPC reminds healthcare professionals that contraception is recommended for women who can become pregnant and are using Mounjaro. It notes that data are limited on how tirzepatide affects the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes.

For women who use an oral contraceptive, the communication advises either of two approaches:

  • adding a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or
  • switching to a non-oral contraceptive method.

The page does not describe the pharmacokinetic data behind the advice, and the full DHPC text was not part of the highlights.

Context

Mounjaro is authorised in the EU, as stated on the EMA page, for adults with type 2 diabetes that is not satisfactorily controlled (alongside diet and physical activity) and for weight management in people with obesity (BMI of 30 kg/m² or more) or overweight (BMI 27 to 30 kg/m²) who have weight-related health problems. Tirzepatide is a dual GIP and GLP-1 receptor agonist; the EMA page does not itself describe the drug class. Delayed gastric emptying is one mechanism by which medicines of this type could alter the absorption of oral drugs, but the EMA highlights do not state a mechanism and this article does not assert one.

What comes next

The communication will reach prescribers once the European Commission decision is made. Readers should consult the DHPC and the product information on EMA's website for the exact wording.

Sources

Sources

  1. EMA: CHMP meeting highlights, 9-12 November 2026

For research use only. Not for human or animal consumption. This article summarizes published research for scientific information only. It is not medical advice and makes no claim about any use in people or animals. These products have not been evaluated or approved by the U.S. Food and Drug Administration (FDA). They are not intended to diagnose, treat or prevent any disease.

Incretin Analogs

Tirzepatide

10, 20, 30 or 50 mg

From $105.00

In stock